Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

5.26
-0.1500-2.77%
Post-market: 5.260.00000.00%18:44 EDT
Volume:172.16K
Turnover:919.36K
Market Cap:79.02M
PE:-1.00
High:5.51
Open:5.41
Low:5.23
Close:5.41
Loading ...

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

GlobeNewswire
·
05 Feb

Jasper Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
10 Jan

Jasper Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
09 Jan

Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital

TIPRANKS
·
09 Jan

RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 Jan

Jasper Therapeutics Inc : Btig Cuts Target Price to $64 From $90

THOMSON REUTERS
·
09 Jan

Jasper Therapeutics Inc : RBC Cuts Target Price to $48 From $68

THOMSON REUTERS
·
09 Jan

Promising Efficacy and Safety of Jasper Therapeutics’ Briquilimab Boosts Buy Rating

TIPRANKS
·
09 Jan

Jasper Therapeutics price target lowered to $64 from $90 at BTIG

TIPRANKS
·
09 Jan

Jasper BEACON data ‘net positive,’ says BMO Capital

TIPRANKS
·
09 Jan

Crude Oil Down 1%; US Weekly Jobless Claims Decline

Benzinga
·
09 Jan

BUZZ-Jasper Therapeutics falls about 50% after early-stage data for skin disease drug

Reuters
·
08 Jan

Jasper Therapeutics Shares Fall 50% Premarket After Early-Stage Data From Co's Skin Disease Drug

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Says Preliminary Study Data for Urticaria Treatment Show Reduced Disease Activity

MT Newswires Live
·
08 Jan

BRIEF-Jasper Therapeutics Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria

Reuters
·
08 Jan

Jasper Therapeutics Inc - Data Supports Commencement of Csu Registrational Program Expected to Commence Second Half of 2025

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Inc - 100% Complete Responses in 240Mg Cohort at 8 Weeks

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data From Beacon Study of Briquilimab in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

GlobeNewswire
·
08 Jan

Jasper Therapeutics: Promising Growth Potential in the Urticaria Market with Briquilimab’s Emerging Efficacy Profile

TIPRANKS
·
07 Jan